Company research
Black Hawk Acquisition Corp
CIK 2000775Updated Nov 13, 2026
BKHA price & chart
Loading TradingView…
NASDAQ:BKHA on TradingView ↗About the company
Black Hawk Acquisition Corporation is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.
In the news
Recent filings
SCHEDULE 13G/A - filed by MIZUHO FINANCIAL GROUP INC regarding Black Hawk Acquisition Corp
SCHEDULE 13G/A - filed by BERKLEY W R CORP regarding Black Hawk Acquisition Corp
SCHEDULE 13G/A - filed by WOLVERINE ASSET MANAGEMENT LLC regarding Black Hawk Acquisition Corp
Other Events
Items 8.01
Submission of Matters to a Vote of Security Holders
Items 5.07
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2026 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||
| AssetsUSD | 26,034,667Source | 23,341,102Source | 71,371,165Source | 25,376,246Source | 73,502,321Source | 70,468,139Source | 24,821,943Source | 72,800,437Source | 23,877,939Source | 72,143,335Source |
| Current assets: | ||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Assets, CurrentUSD | 41,367Source | 44,530Source | 392,504Source | 63,130Source | 139,523Source | 454,970Source | 181,352Source | 205,262Source | 50,790Source | 314,071Source |
| LIABILITIES AND EQUITY | ||||||||||
| LiabilitiesUSD | 4,750,491Source | 3,361,168Source | 2,465,509Source | 5,166,806Source | 2,666,043Source | 2,446,250Source | 4,701,432Source | 2,484,701Source | 3,897,233Source | 2,485,978Source |
| Stockholders’ equity: | ||||||||||
| Additional Paid in CapitalUSD | 4,538Source | — | — | 4,538Source | — | — | 4,538Source | — | 4,538Source | — |
| Retained Earnings (Accumulated Deficit)USD | -4,713,865Source | -3,316,841Source | -2,073,208Source | -5,108,417Source | -2,526,723Source | -1,991,483Source | -4,524,821Source | -2,279,642Source | -3,851,184Source | -2,172,110Source |
| Stockholders' Equity Attributable to ParentUSD | -4,709,124Source | -3,316,638Source | -2,073,005Source | -5,103,676Source | -2,526,520Source | -1,991,280Source | -4,520,080Source | -2,279,439Source | -3,846,443Source | -2,171,907Source |
| Liabilities and EquityUSD | 26,034,667Source | 23,341,102Source | 71,371,165Source | 25,376,246Source | 73,502,321Source | 70,468,139Source | 24,821,943Source | 72,800,437Source | 23,877,939Source | 72,143,335Source |
| Current liabilities: | ||||||||||
| Liabilities, CurrentUSD | 2,335,491Source | 946,168Source | 50,509Source | 2,751,806Source | 251,043Source | 31,250Source | 2,286,432Source | 69,701Source | 1,482,233Source | 70,978Source |
| Additional Financial Items | ||||||||||
| Accrued Liabilities, CurrentUSD | — | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source | 0Source |
| Common Stock, Value, Issued | — | — | — | —Source | — | — | —Source | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | 1,074,736Source | 154,401Source | 88,929Source | 520,542Source | 139,805Source | 658,379Source | 1,329,557Source | 1,915,703Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -109,502Source | -163,314Source | -650,321Source | -553,665Source |
| Cash flows from investing activities: | ||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -600,000Source | — | 50,260,745Source | -69,345,000Source |
| Cash flows from financing activities: | ||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 848,388Source | — | -49,835,745Source | 70,038,407Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 12,052Source | 15,000Source | 11,583Source | 72,914Source | 178,407Source | 101,528Source | 39,521Source | 264,842Source |
| Additional Financial Items | ||||||||||
| General and Administrative ExpenseUSD | — | — | 108,210Source | 311,265Source | 79,215Source | 217,598Source | 24,189Source | 78,769Source | 795,510Source | 492,131Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 1,074,736Source | 154,401Source | 88,929Source | 520,542Source | 139,805Source | 658,379Source | 1,329,557Source | 1,915,703Source |
| Gain (Loss) on Extinguishment of Debt | — | — | —Source | — | — | — | — | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | — | — | — | — | — | — |
| Payments of Financing Costs | — | — | — | — | — | — | — | — | — | — |
| Proceeds from Issuance of Common Stock | — | — | — | — | — | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2026 | Q3 2025 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -138,210Source | -341,265Source | -109,215Source | -247,598Source | -54,189Source | -108,769Source | -915,510Source | -576,076Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 1,074,736Source | 154,401Source | 88,929Source | 520,542Source | 139,805Source | 658,379Source | 1,329,557Source | 1,915,703Source |
| Additional Financial Items | ||||||||||
| General and Administrative ExpenseUSD | — | — | 108,210Source | 311,265Source | 79,215Source | 217,598Source | 24,189Source | 78,769Source | 795,510Source | 492,131Source |
| Interest ExpenseUSD | — | — | 33,226Source | — | 24,381Source | — | 19,449Source | — | 15,454Source | — |
| Interest Income (Expense), NetUSD | — | — | 230,184Source | 494,519Source | 222,525Source | 767,623Source | 213,442Source | 765,911Source | 2,258,631Source | 2,484,264Source |
| Interest Income, OtherUSD | — | — | — | 43Source | — | 517Source | — | 1,237Source | 1,798Source | 7,515Source |
| Other General and Administrative ExpenseUSD | — | — | — | — | — | — | 10,000Source | — | 10,000Source | — |
| Other IncomeUSD | — | — | 1,212,946Source | 495,666Source | 198,144Source | 768,140Source | 193,993Source | 767,148Source | 2,245,067Source | 2,491,779Source |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | — | — | — | — | — | — |
Offerings
Registration 333-292402
- Deal price
- 1.0
- Offering price
- $1.00
Registration 333-292402-01
- Deal price
- 1.0
- Offering price
- $1.00
Filing attachments
blackhawk_ex4-5.htm · S-4/A · 2026-09-04
Exhibit 4.5 NUMBER SHARES CUSIP 925370 108 C- SEE REVERSE FOR CERTAIN DEFINITIONS VESICOR THERAPEUTICS HOLDINGS, INC. INCORPORATED UNDER THE LAWS OF DELAWARE CLASS A COMMON STOCK THIS CERTIFIES THAT is the owner of FULLY PAID AND NON-ASSESSABLE SHARES OF CLASS A COMMON STOCK OF THE PAR VALUE OF $0.0001 EACH OF VESICOR THERAPEUTICS HOLDINGS, INC. (the “Company”), transferable on the books of the Company in person or by duly authorized attorney upon surrender of this…
Read attachment ↗blackhawk_ex99-1.htm · S-4/A · 2026-09-04
Exhibit 99.1 PROXY CARD Black Hawk Acquisition Corporation YOUR VOTE IS IMPORTANT THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS The undersigned, revoking any previous proxies, hereby acknowledges receipt of the Notice of Special Meeting of Stockholders (the “Notice”) and the Joint Proxy Statement/Consent Solicitation Statement/Prospectus (the “Proxy Statement”), and hereby appoints ___________ and ___________, and each of them independently, with full power of substitution, as proxies t…
Read attachment ↗blackhawk_ex4-6.htm · S-4/A · 2026-08-03
EX-4.6 2 blackhawk_ex4-6.htm EXHIBIT 4.6 Exhibit 4.6 FORM OF WARRANT THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED, HYPOTHECATED OR OTHERWISE DISPOSED OF EXCEPT PURSUANT TO (I) AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND ANY APPLICABLE STATE LAWS, (II) TO THE EXTENT APPLICABLE…
Read attachment ↗blackhawk_ex99-1.htm · S-4/A · 2026-08-03
EX-99.1 5 blackhawk_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 PROXY CARD Black Hawk Acquisition Corporation YOUR VOTE IS IMPORTANT THIS PROXY IS SOLICITED BY THE BOARD OF DIRECTORS The undersigned, revoking any previous proxies, hereby acknowledges receipt of the Notice of Special Meeting of Stockholders (the “Notice”) and the Joint Proxy Statement/Consent Solicitation Statement/Prospectus (the “Proxy Statement”), and hereby appoints ___________ and ___________, and each of them independentl…
Read attachment ↗blackhawkacq_ex99-1.htm · 8-K · 2026-03-17
EX-99.1 3 blackhawkacq_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FOR IMMEDIATE RELEASE Vesicor Therapeutics Appoints Michael Tolentino, M.D., as Chief Executive Officer Blackhawk, Calif., March 17, 2026 - Vesicor Therapeutics, Inc., a San Gabriel, California-based early development stage biotechnology corporation focused on the development of p53-based cancer therapeutics delivered via precision-engineered microvesicles and a proposed de-SPAC acquisition target for Black Hawk Acquisition Corpo…
Read attachment ↗blackhawk_ex99-1.htm · S-4/A · 2026-01-23
Exhibit 99.1 Consent to be Named as a Director Nominee In connection with the filing by Black Hawk Acquisition Corporation and Vesicor Therapeutics, Inc. (as co-registrant) of the Registration Statement on Form S-4, File Number 333-292402, (the “Registration Statement”) with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 (17 C.F.R. §230.438) of the Securities Act, to being named in the Registrat…
Read attachment ↗